- Home
- NGNE vs GWRS Comparison
NGNE vs GWRS Comparison
Compare NGNE & GWRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- GWRS
- Stock Information
- Founded
- NGNE 2003
- GWRS 2003
- Country
- NGNE United States
- GWRS United States
- Employees
- NGNE N/A
- GWRS N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- GWRS Water Supply
- Sector
- NGNE Health Care
- GWRS Utilities
- Exchange
- NGNE Nasdaq
- GWRS Nasdaq
- Market Cap
- NGNE 251.9M
- GWRS 286.0M
- IPO Year
- NGNE N/A
- GWRS 2010
- Fundamental
- Price
- NGNE $21.83
- GWRS $10.18
- Analyst Decision
- NGNE Buy
- GWRS
- Analyst Count
- NGNE 6
- GWRS 0
- Target Price
- NGNE $39.83
- GWRS N/A
- AVG Volume (30 Days)
- NGNE 224.0K
- GWRS 36.0K
- Earning Date
- NGNE 05-09-2025
- GWRS 05-14-2025
- Dividend Yield
- NGNE N/A
- GWRS 2.97%
- EPS Growth
- NGNE N/A
- GWRS N/A
- EPS
- NGNE N/A
- GWRS 0.23
- Revenue
- NGNE $925,000.00
- GWRS $53,539,000.00
- Revenue This Year
- NGNE N/A
- GWRS $8.31
- Revenue Next Year
- NGNE N/A
- GWRS $6.52
- P/E Ratio
- NGNE N/A
- GWRS $44.30
- Revenue Growth
- NGNE N/A
- GWRS 3.94
- 52 Week Low
- NGNE $6.88
- GWRS $9.37
- 52 Week High
- NGNE $74.49
- GWRS $13.98
- Technical
- Relative Strength Index (RSI)
- NGNE 62.53
- GWRS 48.31
- Support Level
- NGNE $16.62
- GWRS $10.00
- Resistance Level
- NGNE $18.90
- GWRS $10.22
- Average True Range (ATR)
- NGNE 2.06
- GWRS 0.21
- MACD
- NGNE 0.38
- GWRS -0.00
- Stochastic Oscillator
- NGNE 60.81
- GWRS 39.45
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.